This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B-cell responses that continue to evolve for at least one year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern1. As a result, vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines produces high levels of plasma neutralizing activity against all variants tested1, 2. Here, we examine memory B cell evolution 5 months after vaccination with either Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccines in a cohort of SARS-CoV-2 naïve individuals. Between prime and boost, memory B cells produce antibodies that evolve increased neutralizing activity, but there is no further increase in potency or breadth thereafter. Instead, memory B cells that emerge 5 months after vaccination of naïve individuals express antibodies that are equivalent to those that dominate the initial response. We conclude that memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination.
Bonus — CFP covered this report from Israel a few weeks ago…
“95% of the severe patients are vaccinated”.
“85-90% of the hospitalizations are in Fully vaccinated people.”
“We are opening more and more COVID wards.”
“The effectiveness of the vaccine is waning/fading out”
— Ran Israeli (@RanIsraeli) August 5, 2021
Dr. Kobi Haviv, Director of Jerusalem Hospital
Watch in full screen so you can read the subtitles.
‘Vaccinated account for 95% of severe Covid hospitalizations. Vaccine effectiveness is fading.’